Showing 1301-1310 of 3001 results for "".
- New Resource Center for People Living with Multiple Sclerosishttps://practicalneurology.com/news/new-resource-center-for-people-living-with-multiple-sclerosis/2469307/The Treatment and Adherence Resource Center within MyMSTeam, a social network for individuals living with multiple sclerosis (MS) has officially launched. The Resource Center is designed to help individuals with MS and their families understand the importance of starting treatment and provides ac
- Ozanimod, a New Oral Treatment for Relapsing Multiple Sclerosis, Now Availablehttps://practicalneurology.com/news/ozanimod-a-new-oral-treatment-for-relapsing-multiple-sclerosis-now-available/2469283/The Food and Drug Administration (FDA) approved ozanimod (Zeposia; Bristol Myers Squibb, Princeton, NJ) for treatment of relapsing forms of multiple sclerosis (MS) on March 25, 2020. Ozanimod, 0.92 mg, is a new once-daily oral medication for adults with relapsing MS. Ozanimod
- Ocrelizumab Direct-to-Consumer Advertising—What Clinicians Need to Knowhttps://practicalneurology.com/news/ocrelizumab-direct-to-consumer-advertisingwhat-clinicians-need-to-know/2469121/A new direct-to-consumer (DTC) campaign has been launched for the MS treatment ocrelizumab (Ocrevus; Genentech, South San Francisco, CA). Although the advertisements may resonate with all generations of people living with MS, this campaign specifically targets the millennial generation (those who
- Earlier Ocrelizumab Treatment Reduces Disability Progression, Potentially Has Shorter Infusion Times and Safety in Pregnancyhttps://practicalneurology.com/news/earlier-ocrelizumab-treatment-reduces-disability-progression-potentially-has-shorter-infusion-times-and-safety-in-pregnancy/2469021/In the open-label extension of OPERA I and II trials (NCT01247324 and NCT01412333) fewer participants with relapsing MS who were treated with ocrelizumab (Ocrevus; Genentech
- AAN Issues Guideline on Vaccines for People With Multiple Sclerosishttps://practicalneurology.com/news/aan-issues-guideline-on-vaccines-for-people-with-multiple-sclerosis/2469002/In a guideline published in the current online issue of Neurology, the American Academy of Neurology (AAN) recommends that people with multiple sclerosis (MS) receive recommended vaccinations, including y
- CTAD 2025 Honors Takeshi Iwatsubo, MD, PhD with Lifetime Achievement Awardhttps://practicalneurology.com/news/ctad-2025-honors-takeshi-iwatsubo-md-phd-with-lifetime-achievement-award/2484692/Takeshi Iwatsubo, MD, PhD was recognized at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference as the recipient of this year’s Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. The award celebrates Dr. Iwatsubo’s decades of foundational work in Alzheime
- Catherine Chu, MD, to Lead Pediatric Neurology at Kennedy Krieger and Johns Hopkinshttps://practicalneurology.com/news/catherine-chu-md-to-lead-pediatric-neurology-at-kennedy-krieger-and-johns-hopkins/2475483/Catherine Chu, MD, MA, MMSc, has been named Vice President of Child Neurology of the Kennedy Krieger Institute and will also serve as Director of the Division of Pediatric Neurology and the John M. Freeman Pediatric Epilepsy Center at Johns Hopkins Children’s Center. According to a statement rele
- In Memoriam: Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANAhttps://practicalneurology.com/news/in-memoriam-martin-a-samuels-md-dsc-hon-faan-macp-frcp-fana/2470226/Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANA, the first named Miriam Sydney Joseph Distinguished Professor of Neurology at Harvard Medical School, passed away on June 6, 2023, at age 77.
- New Consensus Statements on Smoldering Disease in Multiple Sclerosis Developedhttps://practicalneurology.com/news/new-consensus-statements-on-smoldering-disease-in-multiple-sclerosis-developed/2470312/An international panel has developed consensus-driven statements on smoldering disease (SD) in multiple sclerosis (MS), including domains such as definition, onset, pathology, clinical and imaging manifestations, and detection modalities. The goal of the panel is to educate the neurology communit
- International Advisory Committee on Clinical Trials in Multiple Sclerosis Suggests New Framework for Defining Progression of Multiple Sclerosishttps://practicalneurology.com/news/international-advisory-committee-on-clinical-trials-in-multiple-sclerosis-suggests-new-framework-for-defining-progression-of-multiple-sclerosis/2470199/The International Advisory Committee on Clinical Trials in Multiple Sclerosis proposed a new mechanism-driven framework for defining progression in multiple sclerosis (MS). The recommendations presented at the 2023 Annual M